[Orimeten in the treatment of advanced carcinoma of the prostate].

Abstract

The authors treated 16 patients with advanced prostate carcinoma after previous orchiectomy and further progression of the disease: 9 patients with Cyclophosphamide + Ftorafur + placebo and seven patients with Cyclophosphamide + Ftorafur + Orimeten. They achieved in particular improvement of the subjective complaints, while in both groups there was objective progression of the disease. In the group with Orimeten the objective progression of the disease was slower than in the group where cytostatics alone were administered.

• Authors: V Vachalovský, V Vomácka
• Journal: Rozhledy v chirurgii : mesicnik Ceskoslovenske chirurgicke spolecnosti (Rozhl Chir) Vol. 68 Issue 4 Pg. 268-71 (Apr 1989) ISSN: 0035-9351 [Print] Czech Republic
• Vernacular Title: Orimeten v lécbĕ pokrocilého karcinomu prostaty.
• PMID: 2501877 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article)

Chemical References

• Antineoplastic Agents
• Aminoglutethimide
• Tegafur
• Cyclophosphamide

Topics

• Aged
• Aged, 80 and over
• Aminoglutethimide (administration & dosage, therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Carcinoma (drug therapy, pathology)
• Cyclophosphamide (administration & dosage)
• Drug Therapy, Combination
• Humans
• Male
• Middle Aged
• Prostatic Neoplasms (drug therapy, pathology)
• Tegafur (administration & dosage)